AstraZeneca is reported to be exploring preliminary talks about acquiring US rival Bristol Myers Squibb (BMS) in a potential mega-merger valued at around $400 billion. The news triggers sharp market moves, with AstraZeneca shares falling roughly 9% in connection with reports of the discussions. Multiple outlets say the combined company could become one of the world’s largest drugmakers by market value.
Context for the speculation includes a long-running debate over consolidation in Big Pharma and AstraZeneca’s potential shift from its prior strategy. Financial Times and other reports highlight investor concerns about a looming patent cliff and the impact on future revenue, alongside possible antitrust scrutiny if a deal advanced. Bloomberg and CNBC frame the move as controversial, with investors and analysts questioning the logic and scale of such a transaction.
Later reporting suggests the situation may not be active: Reuters is cited as saying there are no ongoing discussions, while one account notes that neither company has clearly communicated details to shareholders. That leaves the market weighing whether any talks were exploratory or have been dropped.
